Drug Database
Back to search

Netherlands· NL-9eb9e56ff9dd

Certican 0,75, tabletten 0,75 mg

A everolimus product containing everolimus, registered in Netherlands by Novartis Pharma B.V.. The same ATC class is registered in 9 of our 19 countries.

ATC L04AH02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedCertican 0,75, tabletten 0,75 mgATCL04AH02REGISTER NO.NL-9eb9e56ff9ddPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about everolimusAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Everolimus is registered in 9 of 19 countries.

Countries holding a registration under ATC L04AH02 (everolimus), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose
Search everolimus products by name

Everolimus · ATC L04AH02

9 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of everolimus costs, country by country.

Normalised to the WHO defined daily dose (1.5 mg), the median price runs from $4.19 in United States to $20.09 in Switzerland — a ×4.8 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Everolimus · price per daily dose (1.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$20.09
  • ES Spain$15.84
  • US United States$4.19 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
EVEROLIMUS
Manufacturer
Novartis Pharma B.V.
Country
Netherlands (NL)
ATC code
L04AH02
ATC class
Everolimus
Defined daily dose
1.5 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    30043

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

428 interactions on record for everolimus.

Graded by severity as the source publishes them — 165 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check everolimus against other medicinesHow interaction checks work

Everolimus · interactions on record

428 records

  • 165 severe
  • 255 moderate
  • 8 minor

Most severe, free to view

  • AprepitantA04AD12severe
  • NeomycinA07AA01severe
  • StreptomycinA07AA04severe
  • Polymyxin BA07AA05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Everolimus in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All everolimus products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Certican, Everolimus Ethypharm
  • Belgium · Certican, Everolimus Eg
  • Bulgaria · Еверолимус Крка, Еверолимус Майлан
  • Cyprus · Certican, Everolimus Pharmazac
  • Czechia · Certican, Everolimus Accord
  • Germany · Certican, Everofin
  • Denmark · Certican, Everolimus Krka
  • Estonia · Certican, Everolimus Krka
  • Spain · Certican, Everolimus Accord
  • Finland · Aderolio, Certican
  • France · Certican, Everolimus Arrow
  • United Kingdom (Northern Ireland) · Aderolio, Aderolio 250 Mcg Tablets
  • Greece · Certican, Everolimus Faran
  • Croatia · Certican, Everolimus Krka
  • Hungary · Certican, Everolimus Accord
  • Ireland · Certican, Everolimus Tad
  • Iceland · Afinitor, Certican
  • Italy · Certican, Everolimus Accord
  • Liechtenstein · Afinitor, Votubia
  • Lithuania · Certican, Everolimus Norameda
  • Luxembourg · Certican, Everolimus Eg
  • Latvia · Certican, Everolimus Norameda
  • Malta · Certican, Everolimus Ascend
  • Norway · Afinitor, Certican
  • Poland · Aderolio, Certican
  • Portugal · Certican, Everolimus Ethypharm
  • Romania · Certican, Everolimus Accord
  • Sweden · Certican, Everolimus Avansor
  • Slovenia · Certican, Everolimus Krka
  • Slovakia · Certican, Everolimus Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fc74bbc6-dc22-4ad9-bf53-dcacc55ce1be
GET /v1/drugs/fc74bbc6-dc22-4ad9-bf53-dcacc55ce1be?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h30043_smpc.pdf",
  "strength": null,
  "atc_label": "Everolimus",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg30043",
  "excipients": [
    "BUTYLHYDROXYTOLUEEN (E 321)",
    "CROSPOVIDON (E 1202)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "LACTOSE 0-WATER",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)"
  ],
  "substances": [
    "EVEROLIMUS"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h30043.pdf",
  "authorised_at": "2004/06/10",
  "procedure_number": "SE/H/0356/003",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "30043",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about everolimus.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console